RxDoctor Payments DataLook up a doctor →

Sharad Ghamande, MD

Gynecologic Oncology · Augusta, GANPI 1174500128

Payments from drug & device makers

$8,683,754in general payments, 2019–2025

Across 967 payments — averaging $8980.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$3.8M
  • Seagen Inc.$981K
  • Genmab U.S., Inc.$804K
  • GSK$728K
  • Eisai Inc.$696K
  • Clovis Oncology, Inc.$421K
  • plus $1.3M from 53 others
$6,617in research payments, 2019–2025

Across 19 payments — averaging $348.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$3K
  • EMD Serono, Inc.$2K
  • F. Hoffmann-la Roche AG$1K
  • Pfizer$780

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck226$3,784,715
Seagen Inc.62$980,776
Genmab U.S., Inc.29$804,494
GSK171$727,562
Eisai Inc.73$695,990
Clovis Oncology, Inc.22$420,963
AstraZeneca47$160,204
F. Hoffmann-la Roche AG12$131,459
Tesaro, Inc.41$115,000
Caris MPI, Inc.9$110,400
Chugai Pharmaceutical Co., Ltd.27$104,322
EMD Serono, Inc.10$91,924
Pfizer26$77,388
Karyopharm Therapeutics Inc.6$75,307
Roche Products Limited3$67,415
Iovance Biotherapeutics, Inc.9$64,502
Genentech, Inc.7$56,076
Pharmaand GmbH12$49,806
Incyte Corporation75$34,764
Takeda Pharmaceuticals U.S.A., Inc.9$34,281
Adaptimmune LLC4$29,175
Astrazeneca UK Limited11$21,115
Genmab A/s1$16,000
Acerta Pharma LLC1$9,705
Puma Biotechnology, Inc.4$5,866
Hoffmann-la Roche Limited3$5,025
Sobi, Inc3$3,819
Novartis4$2,046
Dova Pharmaceuticals1$2,000
Taiho Oncology, Inc.12$276
Intuitive Surgical3$202
Daiichi Sankyo Inc.3$126
Biotissue Holdings Inc.1$118
Amniox Medical, Inc.1$107
Bayer4$96
Tersera Therapeutics LLC4$75
AbbVie4$74
LSI Solutions Inc1$71
AMAG Pharmaceuticals, Inc.3$53
Medical Device Business Services, Inc.1$40
Blueprint Medicines Corporation2$37
Sanofi2$35
Fennec Pharmaceuticals, Inc.1$28
Gilead2$28
ANI Pharmaceuticals, Inc.1$27
Spectrum Pharmaceuticals Inc.1$27
Astellas Pharma US Inc1$23
Ipsen Biopharmaceuticals, Inc1$23
Biocompatibles, Inc.1$22
G1 Therapeutics, Inc.1$22
Beigene USA, Inc.1$20
Johnson & Johnson1$19
Rigel Pharmaceuticals, Inc.1$19
Pharmacyclics LLC, An Abbvie Company1$18
Mirati Therapeutics, Inc.1$16
Exelixis Inc.1$16
Lilly USA, LLC1$16
UCB, Inc.1$13
Aspira Women's Health Inc1$7

How this compares

$8,683,754 in reported general payments places this provider in the 95th percentile of 49 gynecologic oncology providers in Georgia.

See all gynecologic oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$254,769
Medicare patients
180
Services billed
9,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →